XYXiangyang Yu

Xiangyang Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangyang Yu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Ma

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    4 shared publications
  • Zhentao Yu

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    3 shared publications
  • Baihua Zhang

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    2 shared publications
  • Calvin Sze Hang Ng

    Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital

    2 shared publications
  • Chenglin Yang

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    2 shared publications
  • Feng Wang

    Department of Minimally Invasive Surgery, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumour Research Institute, Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    Recurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study

    by Feng Wang, Xiangyang Yu, Hao Chen, Dongjie Yan, Lei Yang, Ran Yang, Jianfei Zhu, Zhentao Yu, Yi Han

    Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.

  • Open Access

    Treatment patterns and clinical outcomes of neoadjuvant chemoimmunotherapy for patients with resected oesophageal squamous cell carcinoma: a Chinese multicentre retrospective study

    by Xiangyang Yu, Jianfei Zhu, Feng Wang, Kai Ma, Xiaotong Guo, Baihua Zhang, Lixu Wang, Xin Yu, Shengcheng Lin, Calvin S. H. Ng, et al.

    Background: Several clinical trials of neoadjuvant chemoimmunotherapy (neoCIT) for patients with locally advanced oesophageal carcinoma have been reported recently, with promising anti-tumour efficacy. However, systematic evaluation of the treatment patterns and clinical outcomes in a real-world cohort is lacking. Objectives: This study aimed to describe the real-world treatment patterns and short- and long-term outcomes of neoCIT in patients with resected oesophageal squamous cell carcinoma (ESCC). Design: A multicentre retrospective cohort study. Methods: Data from patients with resected ESCC who received neoCIT in routine clinical practice between January 2020 and December 2022 were retrospectively collected from three tertiary centres in China. Results: A total of 324 consecutive patients were enrolled, and the majority (82.4%) received two cycles of neoCIT. In total, 225 patients achieved a radiographic partial response (PR), resulting in an objective response rate of 69.4%. The rates of minimally invasive oesophagectomy and radical resection were 71.9% and 98.5%, respectively. Fifty-nine patients (18.2%) experienced postoperative complications, and the most common complication was anastomotic leakage (10.2%). The pathological complete response and major pathological response rates were 27.2% and 37.0%, respectively. As of August 31, 2024, the median follow-up was 24.8 months. The estimated 3-year rates of disease-free survival and overall survival were 62.3% and 71.5%, respectively. Multivariate analyses revealed that tumour grade ( p = 0.047), number of neoadjuvant therapy cycles ( p = 0.042), resection status ( p = 0.043), pathological N stage ( p < 0.001) and adjuvant treatment ( p < 0.001) were independent prognostic factors for disease-free survival. However, advanced pathological N stage was identified as the sole independent factor that correlated with worse overall survival ( p < 0.001). Conclusion: This real-world study validates the clinical efficacy and safety of neoCIT for resected oesophageal squamous cell carcinoma while demonstrating encouraging survival outcomes.

  • Open Access

    First case report of immune checkpoint inhibitor therapy to treat secretory carcinoma

    by Xiangyang Yu, Xiaoxing Ye, Mengqi Zhang, Wenting Huang, Calvin S. H. Ng, Zhentao Yu, Kai Ma

    Secretory carcinoma (SC) is a newly defined and exceedingly rare pathologic subtype of lung cancer. We present a case of SC that was initially misdiagnosed as stage IIIB (cT2aN3M0) invasive mucinous adenocarcinoma harboring a programmed cell death ligand 1 tumor proportion score of 10% and an ETV6 - MET fusion gene. The patient received five cycles of toripalimab and pemetrexed plus carboplatin at a local hospital without treatment-related adverse events. Radiologic evaluations prior to third- and fifth-cycle immunochemotherapy indicated that the best response was stable disease. The patient was subsequently reclassified as having stage IB (cT2aN0M0) primary pulmonary malignancy after invasive N staging at our institution, and the primary tumor and mediastinal lymph nodes were removed via a thoracoscope. The tumor exhibited typical morphologic features of SC with immunohistochemical positivity for Mammaglobin and S100 but not for NapsinA or TTF1. Tumor regression was scarcely observed in the surgically resected specimens. This patient was the fifth reported case of primary SC of the lung and the first case of SC treated with immune checkpoint inhibitor therapy that was evaluated in terms of comprehensive safety and efficacy.

  • Open Access

    Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial

    by Xiangyang Yu, Chujian Huang, Longde Du, Chunguang Wang, Yikun Yang, Xin Yu, Shengcheng Lin, Chenglin Yang, Hongbo Zhao, Songhua Cai, et al.


  • Open Access

    Uniportal Robotic Lobectomy and Lymphadenectomy for Invasive Lung Cancer: A Novel Approach and Perioperative Outcomes

    by Shengcheng Lin, Xiangyang Yu, Yafei Xu, Yu Xin, Jie He, Zhentao Yu, Hongbo Zhao, Chenglin Yang, Kai Ma

    Background: Multiport robot‐assisted thoracoscopic surgery (mRATS) has been comprehensively evaluated for its clinical efficacy in numerous studies. Nevertheless, the safety and feasibility of uniportal robotic lobectomy and lymphadenectomy require further validation.Methods: The clinical data of 34 consecutive patients with lung cancer who underwent improved uniportal robotic‐assisted thoracoscopic surgery (uRATS) at our hospital between November 2023 and June 2024 were reviewed retrospectively. Camera‐centered uRATS was conducted using the da Vinci Surgical Xi system (Intuitive Surgical Inc., 1266 Kifer Road, Sunnyvale, CA 94086, USA). Descriptive statistics are expressed as numbers with percentages for categorical data or medians (ranges) or means with standard deviations for continuous data.Results: Improved uRATS lobectomy and lymphadenectomy were conducted in 34 patients with postoperative pathology‐diagnosed invasive lung cancer. Among the patients, the median number of lymph nodes dissected was 24.5 (range 10–42), and the median number of stations with lymph nodes dissected was 8 (range 6–11). The median durations of the operation and the uRATS procedure were 200 min (range, 142–330 min) and 140 min (range, 80–242 min), and the median intraoperative blood loss volume was 20 mL (range, 10–100 mL), respectively. All postoperative complications, including pneumonia (2/34, 5.8%), air leakage > 5 days (2/34, 5.8%), prolonged wound healing (1/34, 2.9%), and arrhythmia (1/34, 2.9%), were graded as Clavien–Dindo grades I–II. There were no cases of wound infection or postoperative 30‐day mortality.Conclusion: The safety and feasibility of uRATS lobectomy and lymphadenectomy using the da Vinci Surgical Xi system have been preliminarily validated.


  • Open Access

    E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma

    by Shengcheng Mm Lin, Xiangyang Yu, Haojie Yan, Yafei Mm Xu, Kai Ma, Xiaoliang Mm Wang, Yeqing Mm Liu, Ahuan Mm Xie, Zhentao Yu

    E2F transcription factors (E2Fs) are a family of transcription factors critical regulators of the cell cycle, apoptosis, and differentiation, thus influencing tumorigenesis. However, the specific roles of E2Fs in lung adenocarcinoma (LUAD) remain unclear. Data from The Cancer Genome Atlas (TCGA) were used. R version. 4.0.3 and multiple databases (TIMER, cBioportal, gene expression profile interaction analysis [GEPIA], LinkedOmics, and CancerSEA) were utilized to investigate mRNA expression, mutational analysis, prognosis, clinical correlations, co-expressed gene, pathway and network, and single-cell analyses. Immunohistochemistry (IHC) confirmed that E2F transcription factor 7 (E2F7) correlated with LUAD. Among the E2Fs, E2F7 was identified by constructing a prognostic model most significantly associated with overall survival (OS) in LUAD patients. The univariate and multivariate Cox regression analyses showed that E2F7, p-T stage, and p-TNM stage were closely related to OS and progression-free survival (PFS) (P < .05) in LUAD. E2F 7/8 were also identified as significantly associated with tumor stage in the GEPIA database. Compared with paracancerous tissues, E2F7 was up-regulated in LUAD by IHC, and E2F7 might be positively correlated with larger tumors and higher TNM stages. E2F7 may primarily regulate DNA repair, damage, and cell cycle processes and thus affect LUAD tumorigenesis, invasion, and metastasis by LinkedOmics and CancerSEA. E2F7 serves as a potential prognostic biomarker for LUAD.


  • Open Access

    Lung cancer surgery: innovations and future perspectives

    by Xiangyang Yu, Feng Wang, Kai Ma, Zhentao Yu

    Nine decades ago in 1933, Evarts A. Graham performed the first successful pneumonectomy in a patient with primary pulmonary squamous cell carcinoma. The patient survived for another 30 years, which drew the curtain on the surgical treatment of lung cancer. Surgical resection continues to be the cornerstone of multidisciplinary treatment for patients with early-stage non-small cell lung cancer and a proportion of those with locally advanced disease. Moreover, recent years have seen developments in automatic control, biomechanics, robotics, image transmission, artificial intelligence, three-dimensional reconstruction and printing, biological pharmacy, and molecular biology. Therefore, there is now an increasing focus on how to integrate these technologies into lung cancer surgery to improve quality of life, resect the tumor accurately, expand the population that is suitable for surgical management, predict disease recurrence with better accuracy, and ultimately achieve long-term survival. This article systematically reviews the innovative achievements that may be detrimental to current clinical practice and in future clinical trials, and simultaneously provides a brief overview of the polyvagal perspective in this field.


  • Open Access

    Survival After Lobectomy Versus Sublobar Resection for Stage IA Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

    by Xiangyang Yu, Zirui Huang, Mengqi Zhang, Yongbin Lin, Rusi Zhang, Yingsheng Wen, Xuewen Zhang, Longjun Yang, Dechang Zhao, Lanjun Zhang

    Background: Due to the low incidence of pulmonary large cell neuroendocrine carcinoma (LCNEC), the survival analysis for comparing lobectomy and sublobar resection (SLR) for stage IA LCNEC remains scarce. Methods: Patients diagnosed with pathological stage IA LCNEC between 1998 and 2016 were extracted from the Survenillance, Epidemiology, and End Results (SEER) database. The oncological outcomes were cancer-specific survival (CSS) and overall survival (OS). Kaplan-Meier analysis and Cox multivariate analysis were used to identify the independent prognostic factors for OS and CSS. Furthermore, propensity score matching (PSM) was performed between SLR and lobectomy to adjust the confounding factors. Results: A total of 308 patients with stage IA LCNEC met the inclusion criteria: 229 patients (74.4%) received lobectomy and 79 patients (25.6%) received SLR. Patients who underwent SLR were older (PConclusions: Although SLR is not inferior to lobectomy in terms of oncological outcomes for patients with stage IA LCNEC, more lymph nodes can be dissected or sampled during lobectomy. Lobectomy should be considered as a standard procedure for patients with early-stage LCNEC who are able to withstand lobectomy.